Clinical trials: Type 2 Diabetes Risk
- Condition Type 2 Diabetes Risk
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Acute Liver Injury
Acute Liver Injury in Patients on Dapagliflozin
To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695095
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 424,091 people
- Sponsor
- AstraZeneca
Acute Kidney Injury
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
To compare, by insulin use at the index date, the incidence of hospitalization for acute kidney injury (AKI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695082
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 539,310 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes
This study is conducted in Asia. The aim of this study is to assess the efficacy of a pre-pregnancy life style intervention to reduce the risk of diabetes and prediabetes.
- Trial name
- Jom Mama (NCT02617693)
- Testing
- lifestyle intervention, standard antenatal care
- Where
- Malaysia
- Volunteers
- 552 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are <8 years of age.
- Trial name
- PETITE-T1D (NCT05757713)
- Testing
- teplizumab
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Sanofi
Severe Complications of Urinary Tract Infections
Complications of UTI in Patients on Dapagliflozin
The objective of this study is to compare, by insulin use at the index date, the sex-specific incidence of hospitalization or emergency department (ED) visit for severe complications of urinary tract infections (UTI), defined as…
- Trial name
- NCT02695173
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 683,380 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation.
- Trial name
- NCT03492580
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 714,582 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes, Diabetes Mellitus, Type 1
Changing Diabetes® World Tour
This study is conducted in the Middle East, Northern Africa and Europe. The aim of this study is to contribute to the design of a simple screening strategy for countries in scope, by exploring the association between risk factors…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01437072
- Testing
- No treatment given
- Where
- 3 sites in Portugal, Saudi Arabia and 1 more
- Volunteers
- 8,304 people
- Sponsor
- Novo Nordisk A/S